Bristol-Myers Squibb Company with price, financials, news flow, and insider context in one page.
Bristol-Myers Squibb Company is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where BMY sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
This page is structured for research context, not a trade call. It gives you a clean read on where BMY sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 11.49B | 2.68B | 757M |
| Q4 2025 | 12.5B | 1.09B | 1.6B |
| Q3 2025 | 12.22B | 2.2B | 5.99B |
| Q2 2025 | 12.27B | 1.31B | 3.56B |
Xbox consoles, Nintendo's new Switch 2 and Valve's Steam Deck are just some of the gadgets seeing price hikes in recent months.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Bristol-Myers Squibb Company (BMY) — questions investors ask
What is the current stock price of Bristol-Myers Squibb Company (BMY)?
Bristol-Myers Squibb Company (BMY) is trading at $57.52, up 3.85% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Bristol-Myers Squibb Company's market capitalization?
Bristol-Myers Squibb Company has a market capitalization of about 117.46B, derived from the latest share price and shares outstanding.
When is Bristol-Myers Squibb Company's next earnings date?
Bristol-Myers Squibb Company is next expected to report earnings on Jul 30, 2026. The BMY earnings page tracks the estimate and reporting history.
What is Bristol-Myers Squibb Company's P/E ratio?
Bristol-Myers Squibb Company trades at a forward price-to-earnings ratio of 9.33 — one measure of how the market is pricing its future earnings.
What is BMY's 52-week trading range?
Over the past 52 weeks, BMY has traded between $42.52 and $62.89.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does Bristol-Myers Squibb Company pay a dividend?
Bristol-Myers Squibb Company currently carries a dividend yield of about 100.0%.
What is the analyst price target for BMY?
The mean analyst price target for BMY is $63.08, with an overall analyst view of None.
A public stock page should answer the first research questions before asking for a signup.
This BMY page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.